BIOMAT Database Logo BIOMAT Database Logo

Inhibition of collagen gene expression in systemic sclerosis dermal fibroblasts by mithramycin. 2005

N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
Division of Rheumatology, Department of medicine, Thomas Jefferson University, Philadelphia, PA 19107-5041, USA.

BACKGROUND The anti-tumour antibiotic mithramycin is also a potent inhibitor of fibrosis after glaucoma surgery. This drug displays high affinity binding to GC-rich sequences in DNA, including those present in the promoter of the gene encoding the alpha1 chain of type I collagen (COL1A1). OBJECTIVE To evaluate the effects of mithramycin on COL1A1 expression in systemic sclerosis fibroblasts. METHODS Confluent cultures of dermal fibroblasts from patients with recent onset diffuse systemic sclerosis were treated with mithramycin in vitro. Cell viability and protein expression were examined by fluorescence and confocal imaging. Type I collagen production was analysed by confocal imaging and metabolic labelling. COL1A1 messenger RNA levels and stability were assessed by northern hybridisation, and COL1A1 transcription was examined by transient transfections. RESULTS Treatment of systemic sclerosis fibroblasts with mithramycin (10-100 nmol/l) did not cause significant cytotoxicity. Type I collagen biosynthesis decreased by 33-40% and 50-70% in cells cultured with mithramycin at 10 nmol/l and 100 nmol/l, respectively. Mithramycin at 50 nmol/l decreased COL1A1 mRNA levels by 40-60%. The effects of mithramycin on collagen gene expression were mediated by transcriptional and post-transcriptional mechanisms as shown by the reduction of COL1A1 promoter activity and by a decrease in the stability of these transcripts, respectively. CONCLUSIONS Mithramycin causes potent inhibition of collagen production and gene expression in systemic sclerosis dermal fibroblasts in vitro in the absence of cytotoxic effects. These results suggest that this drug may be an effective treatment for the fibrotic process which is the hallmark of systemic sclerosis.

UI MeSH Term Description Entries
D008926 Plicamycin A tricyclic pentaglycosidic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA. It is used as a fluorescent dye and as an antineoplastic agent, especially in bone and testicular tumors. Plicamycin is also used to reduce hypercalcemia, especially that due to malignancies. Aureolic Acid,Mithramycin,Mitramycin
D011500 Protein Synthesis Inhibitors Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. Protein Synthesis Antagonist,Protein Synthesis Antagonists,Protein Synthesis Inhibitor,Antagonist, Protein Synthesis,Antagonists, Protein Synthesis,Inhibitor, Protein Synthesis,Inhibitors, Protein Synthesis,Synthesis Antagonist, Protein,Synthesis Inhibitor, Protein
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090602 Collagen Type I, alpha 1 Chain A fibrillar collagen found predominantly in BONE and SKIN. COL1A1 Protein,Collagen Type I, alpha 1 Subunit,Collagen alpha 1 (I),Pro alpha 1 Collagen,Pro-alpha1(I) Collagen,Procollagen alpha1(I),Type I Collagen alpha 1,Protein, COL1A1
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis

Related Publications

N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin.
April 2006, Arthritis and rheumatism,
N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
Regulation of interleukin-4 on collagen gene expression by systemic sclerosis fibroblasts in culture.
June 1996, Journal of dermatological science,
N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
Spontaneous cytokine gene expression by cultured skin fibroblasts of systemic sclerosis. Correlation with collagen synthesis.
January 1998, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I.
July 2000, Arthritis and rheumatism,
N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts.
November 1998, Arthritis and rheumatism,
N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis.
October 2013, Arthritis research & therapy,
N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
Characterization of dermal collagen in systemic sclerosis.
April 1979, The British journal of dermatology,
N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
MicroRNA-21 and microRNA-29a modulate the expression of collagen in dermal fibroblasts of patients with systemic sclerosis.
May 2019, Autoimmunity,
N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
Downregulation of Aquaporin3 in Systemic Sclerosis Dermal Fibroblasts.
June 2017, Iranian journal of allergy, asthma, and immunology,
N Sandorfi, and N Louneva, and E Hitraya, and G Hajnoczky, and B Saitta, and S A Jimenez
Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts.
March 2015, Archives of dermatological research,
Copied contents to your clipboard!